Autonomix Medical, Inc. (NASDAQ:AMIX) Short Interest Update
by Michael Walen · The Markets DailyAutonomix Medical, Inc. (NASDAQ:AMIX – Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totaling 1,543,188 shares, an increase of 1,052.8% from the December 15th total of 133,864 shares. Based on an average daily volume of 12,719,755 shares, the short-interest ratio is presently 0.1 days. Currently, 23.8% of the shares of the stock are sold short. Currently, 23.8% of the shares of the stock are sold short. Based on an average daily volume of 12,719,755 shares, the short-interest ratio is presently 0.1 days.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Autonomix Medical in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $5.00.
Check Out Our Latest Stock Analysis on AMIX
Autonomix Medical Stock Performance
Shares of NASDAQ AMIX traded down $0.01 during mid-day trading on Monday, reaching $0.51. 1,691,812 shares of the company’s stock were exchanged, compared to its average volume of 9,488,779. Autonomix Medical has a 52-week low of $0.47 and a 52-week high of $3.33. The company’s 50-day moving average is $0.76 and its 200-day moving average is $1.06.
Autonomix Medical (NASDAQ:AMIX – Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($1.38) EPS for the quarter, meeting analysts’ consensus estimates of ($1.38). Equities analysts anticipate that Autonomix Medical will post -10 earnings per share for the current year.
About Autonomix Medical
Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.